Mucormycosis: the clinical spectrum
Keywords:Clinical profile, Diabetes, Mucormycosis
Background: Mucormycosis is a rare opportunistic fungal infection typically affecting diabetic or immunosuppressed patients. In most of the cases, infection is caused by inhalation of fungal spores. The aim of the study is to assess the different modes of presentation, risk factors management and prognosis of patients with mucormycosis.
Methods: It is a retrospective study conducted in Father Muller medical college hospital between January 2016 to October 2017 and included all patients hospitalized for mucormycosis confirmed by mycological and /or histological findings. This study was approved by the institutional research and ethics committee. All case records were identified from in patient MRD with the diagnosis of mucormycosis over the last one year. For each case taken, the clinical information was recorded from case sheet
Results: Out of the 7 cases studied 5 (71.4%) had rhinoorbital involvement 28.6% had pulmonary involvement with hemoptysis being the primary symptom. The mean age of the affected population was 55.7 years. Uncontrolled diabetes mellitus was the most common predisposing factor as seen in 71.4% cases with mean Hba1c levels 13. The mean ESR in present study was 79. There was increased WBC count in all the cases studied with neutrophilic predominance. Urine ketones was positive (++) in all the cases of diabetes with rhinoorbital involvement.
Conclusions: Uncontrolled diabetes mellitus is a predisposing factor for mucormycosis. Elevated ESR was noted in all the cases.
Torres-Narbona M, Guinea J, Munoz P, Bouza E. Zygomycetes and zygomycosis in the new era of antifungal therapies. Spanish J Chemotherapy. 2007 Dec;20(4):375-86.
Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. European Journal of Clinical Microbiology and Infectious Diseases. 2006 Apr 1;25(4):215-29.
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infection. 2004 Jan 1;10:31-47.
Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrobial Agents. 2006 Jun 1;27:3-6.
Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, et al. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and a critical review of the literature. Int J Infectious Dis. 2011 Aug 1;15(8):e533-40.
Gupta SK. Clinical profile of mucormycosis: a descriptive analyses. Int J Sci Stud. 2017;5(6):160‐3.
Talmi YP, Goldschmied-Reouven A, Bakon M, Barshack I, Wolf M, Horowitz Z, et al. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngology-Head Neck Surg. 2002 Jul;127(1):22-31.
Nezafati S, Kazemi A, Asgari K, Bahrami A, Naghili B, Yazdani J. Rhinocerebral mucormycosis, risk factors and the type of oral manifestations in patients referred to a university hospital in Tabriz, Iran 2007 to 2017. Mycoses. 2018 Jun 13.
Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgraduate Med J. 2009 Nov 1;85(1009):573-81.
Ghafur A, Shareek PS, Senthur NP, Vidyalakshmi PR, Ramasubramanian V, Parameswaran A, et al. Mucormycosis in patients without cancer: a case series from a tertiary care hospital in South India. J Association Physicians India. 2013 May;61:11.
Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis-The bitter and the sweet. PLoS Pathogens. 2017 Aug 3;13(8):e1006408.
He R, Hu C, Tang Y, Yang H, Cao L, Niu R. Report of 12 cases with tracheobronchial mucormycosis and a review. Clin Respiratory J. 2018 Apr;12(4):1651-60.